Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data

 
• By Sue Sutter
  
Baseball backstop
Amylyx's withdrawal pledge provided a nonbinding backstop to FDA's decision to approve Relyvrio on the basis of a single study. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews